The Dose and the duration of frontline therapy with Imatinib does not affect response to Dasatinib in Imatinib-Resistant or -intolerant patients with chronic myeloid leukemia (CML). Results from a real Life-Based Italian Multicenter retrospective study on 124 Patients

GIUSEPPE VISANI;MASSIMO BRECCIA;PIER PAOLO PICCALUGA;ANTONELLA GOZZINI;GIORGINA SPECCHIA;ENRICO MONTEFUSCO;ENRICA MORRA;MARIO ANNUNZIATA;LUIGIANA LUCIANO;ANDREA CAMERA;FRANCESCO CAVAZZINI;FABIO STAGNO;DI RAIMONDO, FRANCESCO;PATRIZIA PREGNO;FRANCESCA PIRILLO;VALERIA SANTINI;ALBERTO BOSI;MATTEO PACILLI;ESTER PUNGOLINO;EMILIO USALA;EMANUELE ANGELUCCI;MONICA CRUGNOLA;GIANNI BINOTTO;ELENA MAINO;FEDERICA LOSCOCCO;SARA BARULLI;GIUSEPPINA NICOLINI;ANTONIO CUNEO;ROBERTO LATAGLIATA;FELICETTO FERRARA;AND ALESSANDRO ISIDORI

2009-01-01